Risk score for venous thromboembolism

{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}}],"level_type_clusion_I":"Patients population","level_type_clusion_other":"","clusion_I":"• Patient aged 18 years or older • Patient having: - Either metastatic cancer, regardless of its location (except for hematopoietic cancers), - Or one of the following cancers, at all stages of development: stomach, ovary, pancreas, lung, bladder, testicle • Patient: - For whom the cancer is currently being treated or - For whom the cancer treatment is scheduled or - Who do not have any cancer treatment in progress but who gave received a treatment (in the last 3 years) via chemotherapy or radiotherapy or hormone therapy or targeted therapies • In order to be included in the study, the subject for whom a search of additional biological parameters will be carried out must: - having given their free and informed consent in writing, - accept an additional blood sample be taken on the day of inclusion.","clusion_E":""}